Literature DB >> 10078990

Comparison between dopamine transporter affinity and self-administration potency of local anesthetics in rhesus monkeys.

K M Wilcox1, I A Paul, W L Woolverton.   

Abstract

Local anesthetics bind to dopamine transporters and inhibit dopamine uptake in rodent brain. Additionally, local anesthetics are self-administered in rhesus monkeys. The present study determined binding affinities of cocaine and five local anesthetics at dopamine transporters in rhesus monkey brain, and compared binding affinities to published self-administration potencies in rhesus monkeys. The affinity order at dopamine transporters was cocaine > dimethocaine > tetracaine > procaine > or = chloroprocaine > lidocaine. The correlation between dopamine transporter affinities and self-administration potencies was significant. Binding affinities were also determined at sodium (Na2+) channels in rhesus monkey brain. There was not a significant correlation between Na2+ channel affinities and self-administration potencies Local anesthetics with high dopamine transporter and low Na2+ channel affinities were self-administered, whereas those with either high or low affinity at both sites were not consistently self-administered. These data suggest that affinity at dopamine transporters is related to the reinforcing effects of local anesthetics in rhesus monkeys, and Na2+ channel effects may interfere with the reinforcing effect of these drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10078990     DOI: 10.1016/s0014-2999(98)00967-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Cocaine disinhibits dopamine neurons in the ventral tegmental area via use-dependent blockade of GABA neuron voltage-sensitive sodium channels.

Authors:  Scott C Steffensen; Seth R Taylor; Malia L Horton; Elise N Barber; Laura T Lyle; Sarah H Stobbs; David W Allison
Journal:  Eur J Neurosci       Date:  2008-11       Impact factor: 3.386

2.  Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling.

Authors:  K A Levy; Z D Brodnik; J K Shaw; D A Perrey; Y Zhang; R A España
Journal:  Psychopharmacology (Berl)       Date:  2017-06-30       Impact factor: 4.530

Review 3.  Neuroimaging and drug taking in primates.

Authors:  Kevin S Murnane; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2011-03-01       Impact factor: 4.530

4.  Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys.

Authors:  Heather L Kimmel; Jonathon A Nye; Ronald Voll; Jiyoung Mun; Jeffrey Stehouwer; Mark M Goodman; John R Votaw; F I Carroll; Leonard L Howell
Journal:  Synapse       Date:  2012-03-16       Impact factor: 2.562

Review 5.  Nonhuman primate neuroimaging and the neurobiology of psychostimulant addiction.

Authors:  Leonard L Howell; Kevin S Murnane
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 6.  Nonhuman primate neuroimaging and cocaine medication development.

Authors:  Leonard L Howell
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

7.  Chronic treatment with monoamine oxidase-B inhibitors decreases cocaine reward in mice.

Authors:  Ming-Che Ho; Chianfang G Cherng; Yen-Ping N Tsai; Chih-Yuan Chiang; Jia-Ying Chuang; Shu-Fang Kao; Lung Yu
Journal:  Psychopharmacology (Berl)       Date:  2009-04-03       Impact factor: 4.530

8.  Changes in dopamine transporter binding in nucleus accumbens following chronic self-administration cocaine: heroin combinations.

Authors:  Lindsey P Pattison; Scot McIntosh; Tammy Sexton; Steven R Childers; Scott E Hemby
Journal:  Synapse       Date:  2014-06-19       Impact factor: 2.562

9.  Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition.

Authors:  Zachary D Brodnik; Mark J Ferris; Sara R Jones; Rodrigo A España
Journal:  ACS Chem Neurosci       Date:  2016-12-29       Impact factor: 4.418

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.